Powder and solvent for\u00a0suspension for\u00a0injection\u00a0Live vaccine against measles,
mumps and rubella<\/p>\n\n\n\n
MM-RVAXPRO is a vaccine containing measles, mumps, and rubella viruses that have been weakened.\u00a0When the vaccine is given to a person, the immune system (the body’s natural defense system) will produce\u00a0antibodies\u00a0against measles, mumps, and rubella viruses.\u00a0The antibodies\u00a0help to defend against\u00a0infection\u00a0caused by these\u00a0viruses.<\/p>\n\n\n\n
MM-RVAXPRO is given to protect you or your child against measles, mumps, and rubella.\u00a0The vaccine can be given to people who are 12 months or older.<\/p>\n\n\n\n
MM-RVAXPRO can in special circumstances be administered to children from 9 to 12 months of age<\/p>\n\n\n\n
MM-RVAXPRO can also be given for measles outbreaks or post-exposure vaccinations, or to previously unvaccinated people older than 9 months who are in contact with susceptible pregnant women, and to people who may be susceptible to mumps and rubella.<\/p>\n\n\n\n
Although MM-RVAXPRO contains live\u00a0viruses, they are too weak to cause measles, mumps, or rubella in healthy people.<\/p>\n\n\n\n
Talk to a doctor or pharmacist before getting the person to be vaccinated M \u2011 M \u2011 RVAXPRO if he\/she has had any of the following:<\/p>\n\n\n\n
As with other vaccines, MM-RVAXPRO may not result in complete protection in all vaccines.\u00a0In addition, if the person to be vaccinated has already been exposed to the measles, mumps, or rubella virus without having already become ill, MM-RVAXPRO may not be able to prevent the disease from breaking out.<\/p>\n\n\n\n
MM-RVAXPRO can be given to people who have recently (within 3 days) been in contact with a measles case and who are in the incubation period for the disease. However, MM-RVAXPRO can not always prevent the disease from breaking out in these cases.<\/p>\n\n\n\n
Tell your doctor or pharmacist if the person to be vaccinated is taking or has recently taken any other medicines (or other vaccines).<\/p>\n\n\n\n
Vaccination with MM-RVAXPRO should be postponed for at least 3 months after a blood or plasma transfusion or after administration of immunoglobulin (IG). After vaccination with M \u2011 M \u2011 RVAXPRO, IG should not be given for 1 month, unless your doctor tells you otherwise.<\/p>\n\n\n\n
If a tuberculin test is to be performed, it should be done either before, at the same time, or 4 to 6 weeks after vaccination with MM-RVAXPRO.<\/p>\n\n\n\n
MM-RVAXPRO can be given at the same time as Prevenar and\/or hepatitis A vaccine, but at a different injection site (eg in the other arm or leg).<\/p>\n\n\n\n
MM-RVAXPRO can be given with some routine vaccinations to children that may be suitable to be given at the same time. For vaccines that cannot be given concomitantly, MM-RVAXPRO should be given 1 month before or after administration of these vaccines.<\/p>\n\n\n\n
MM-RVAXPRO should not be given to pregnant women. Women of childbearing potential should take the necessary precautions to avoid pregnancy for 1 month, or according to the doctor’s recommendation, after receiving the vaccine.<\/p>\n\n\n\n
Tell your doctor if you are breastfeeding or intend to breastfeed.\u00a0Your doctor will decide if you should receive MM-RVAXPRO.<\/p>\n\n\n\n
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this vaccine.<\/p>\n\n\n\n
There is no evidence that MM-RVAXPRO affects the ability to drive or use machines.<\/p>\n\n\n\n
MM-RVAXPRO contains sodium<\/strong><\/p>\n\n\n\n This medicine contains less than 1 mmol (23 mg)\u00a0sodium\u00a0per\u00a0dose, ie essentially ‘sodium-free’.\u00a0is next to “sodium-free”.<\/p>\n\n\n\n MM-RVAXPRO contains potassium<\/strong><\/p>\n\n\n\n This medicine contains less than 1 mmol (39 mg)\u00a0potassium\u00a0per\u00a0dose, ie essentially ‘potassium’.\u00a0is next to “potassium free”<\/p>\n\n\n\n MM-RVAXPRO contains sorbitol (E 420)<\/strong><\/p>\n\n\n\n This medicine contains 14.5 mg sorbitol per\u00a0dose.\u00a0The additive effect\u00a0of concomitantly administered drugs containing sorbitol (or fructose) and pre-administration of sorbitol (or fructose) should be considered.<\/p>\n\n\n\n MM-RVAXPRO should be injected into the muscle or under the skin either on the outside of the thigh or on the upper arm.\u00a0In young children, the thigh is usually recommended for intramuscular\u00a0injection, while the upper arm is recommended as an injection site in older people.\u00a0MM-RVAXPRO should not be injected into the bloodstream.<\/p>\n\n\n\n MM-RVAXPRO is given as follows:<\/p>\n\n\n\n Preparation instructions intended for healthcare professionals can be found at the end of the package leaflet.<\/p>\n\n\n\n Like all vaccines and medicines, this vaccine can cause\u00a0side effects, although not everybody gets them.<\/p>\n\n\n\n The following side effects have been reported with the use of M \u2011 M \u2011 RVAXPRO: <\/p>\n\n\n\n * These\u00a0side effects\u00a0have been reported with the use of MM-RVAXPRO or the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., or its monovalent (individual) components, when used in the market and\/or in\u00a0clinical trials.<\/p>\n\n\n\n Keep this vaccine out of the reach and sight of children.<\/p>\n\n\n\n Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiration date is the last day of the specified month.<\/p>\n\n\n\n Store and transport cold (2 \u00b0 C \u2011 8 \u00baC).<\/p>\n\n\n\n Store the vial of powder in the outer carton. Sensitive to light.<\/p>\n\n\n\n Do not freeze.<\/p>\n\n\n\n Vaccines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of vaccines that are no longer in use. These measures will help to protect the environment.<\/p>\n\n\n\n The active substances are:<\/p>\n\n\n\n After reconstitution , one dose (0.5 ml) contains:<\/p>\n\n\n\n Measles virus 1<\/sup> Enders Edmonston strain (live, attenuated) not less than 1×10 3 <\/sup> TCID 50<\/sub> *<\/p>\n\n\n\n Parotitic virus 1<\/sup> Jeryl Lynn TM<\/sup> strain (B level) (live, attenuated) not less than 12.5×10 3 <\/sup> TCID 50<\/sub> *<\/p>\n\n\n\n Rubella virus 2<\/sup> Wistar RA 27\/3 strain (live attenuated) not less than 1×10 3<\/sup> TCID 50<\/sub> *<\/p>\n\n\n\n * 50% infectious dose in tissue culture.<\/p>\n\n\n\n 1<\/sup>\u00a0produced in cell culture from the chicken embryo.<\/p>\n\n\n\n 2<\/sup> produced in WI-38 human diploid lung fibroblasts.<\/p>\n\n\n\n Other ingredients are:<\/p>\n\n\n\n Powder:<\/p>\n\n\n\n Sorbitol (E 420), sodium phosphate (NaH\u00a02<\/sub>\u00a0PO\u00a04<\/sub>\u00a0\/ Na\u00a02<\/sub>\u00a0HPO\u00a04<\/sub>\u00a0), potassium phosphate (KH\u00a02<\/sub>\u00a0PO\u00a04<\/sub>\u00a0\/ K\u00a02<\/sub>\u00a0HPO\u00a04<\/sub>\u00a0), sucrose, hydrolyzed gelatin, medium 199 with Hanks salt, MEM,\u00a0sodium\u00a0-L-\u00a0glutamate,\u00a0neomycin, phenol red, sodium bicarbonate (NaHCO\u00a03<\/sub>\u00a0),\u00a0hydrochloric acid\u00a0(\u00a0HCl\u00a0) (to regulate\u00a0pH\u00a0) and sodium hydroxide (NaOH) (to regulate\u00a0pH\u00a0).<\/p>\n\n\n\n Diluent:<\/p>\n\n\n\n Water for injections.<\/p>\n\n\n\n The vaccine is a powder for solution for\u00a0injection,\u00a0suspended\u00a0in single-dose vials, which should be mixed with the diluent provided.<\/p>\n\n\n\n The diluent is clear and colorless. The powder is a light yellow compact cake of powder crystals.<\/p>\n\n\n\n MM-RVAXPRO is available in packs of 1, 5 and 10. Not all pack sizes may be marketed.<\/p>\n\n\n\n Marketing Authorization Holder: MSD VACCINS, 162 avenue Jean Jaur\u00e8s, 69007 Lyon, France<\/p>\n\n\n\n Manufacturer responsible for batch release: Merck Sharp and Dohme, BV, Waarderweg, 39, 2031 BN Haarlem, The Netherlands<\/p>\n\n\n\n Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n\n\n\n MM-RVAXPRO is a vaccine containing measles, mumps and rubella viruses that has been weakened. When the vaccine is given to a person, the immune system (the body’s natural defense system) will produce antibodies against measles, mumps and rubella viruses. The antibodies help to defend against infection caused by these viruses .<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,15580],"tags":[17751,17743,17746,17750,17749,17744,2356,17747,17748],"class_list":["post-18125","post","type-post","status-publish","format-standard","hentry","category-medicines","category-m","tag-benefits-of-mm-rvaxpro","tag-measles-vaccine","tag-mm-rvaxpro","tag-mm-rvaxpro-side-effects","tag-mm-rvaxpro-vaccine","tag-mumps-vaccine","tag-vaccine","tag-what-is-mm-rvaxpro","tag-what-mm-rvaxpro-is-used-for"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/18125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=18125"}],"version-history":[{"count":5,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/18125\/revisions"}],"predecessor-version":[{"id":18164,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/18125\/revisions\/18164"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=18125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=18125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=18125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How to use MM-RVAXPRO<\/h2>\n\n\n\n
Possible side effects<\/h2>\n\n\n\n
Presence<\/td> Side effect<\/td><\/tr> Very common (may affect more than 1 in 10 people vaccinated)<\/td> fever (38.5 \u00b0 C or higher). Redness\u00a0at the injection site;\u00a0injection site pain;\u00a0swelling at the injection site.<\/td><\/tr> Common (may affect up to 1 in 10 people vaccinated)<\/td> rash (including measles-like rash). Bruising at the injection site.<\/td><\/tr> Uncommon (may affect up to 1 in 100 people vaccinated)<\/td> stuffy nose and sore throat;\u00a0upper respiratory tract infection or viral infection;\u00a0Runny nose. crying.diarrhea, vomiting.hives.rash at the injection site.<\/td><\/tr> No known frequency (The occurrence can not be calculated from the available data) *<\/td> aseptic\u00a0meningitis\u00a0(fever, nausea, vomiting, headache, stiff neck, and sensitivity to light);\u00a0swollen testicles;\u00a0middle ear\u00a0infection;\u00a0inflamed salivary glands;\u00a0atypical\u00a0measles (described in patients who have received a vaccine with inactivated measles virus, usually given before 1975). swollen\u00a0lymph nodes\u00a0.more easily affected by bruising or bleeding\u00a0.severe\u00a0allergic reaction\u00a0which may include difficulty breathing, swollen face, local swelling, swelling of the arms and legs. irritability.Seizures (attacks) without fever;\u00a0seizures (attacks) with fever in children;\u00a0unsteady gait;\u00a0dizziness;\u00a0diseases including\u00a0inflammation\u00a0of the nervous system (brain and\/or spinal cord).a disease consisting of muscle weakness, abnormal sensations, tingling in the arms, legs, and upper body (\u00a0Guillain-Barr\u00e9 syndrome\u00a0).headache;\u00a0fainting;\u00a0nerve problems that can cause weakness, tingling, or numbness;\u00a0disorders of the optic nerve. secretion and\u00a0itching\u00a0of the eyes with crusting on the eyelids (\u00a0conjunctivitis\u00a0).retinitis (in the eyes) with vision changes.deafness.cough;\u00a0lung infection with or without fever. nausea.itching;\u00a0inflammation\u00a0of the adipose tissue under the skin;\u00a0red or purple, flat, pinhead-sized dots under the skin;\u00a0hard elevations of the skin;\u00a0severe disease with sores or blisters on the skin, mouth, eyes, and\/or genitals (Stevens-Johnson syndrome).pain and\/or swelling in joints (usually transient and rarely\u00a0chronic\u00a0);\u00a0muscle aches.short-term burning and\/or stabbing pain at the injection site;\u00a0blisters and\/or hives at the injection site\u00a0.general malaise (feeling sick);\u00a0swelling;\u00a0tenderness. inflammation\u00a0of the blood vessels.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n How to store MM-RVAXPRO<\/h2>\n\n\n\n
Contents of the pack and other information<\/h2>\n\n\n\n
Content declaration<\/h2>\n\n\n\n
What the medicine looks like and contents of the pack<\/h2>\n\n\n\n
Marketing Authorization Holder and Manufacturer<\/h2>\n\n\n\n
Belgium \/ Belgique \/ Belgien<\/strong>MSD BelgiumTel: +32 (0) 27766211dpoc_belux@merck.com<\/td> Lithuania<\/strong>UAB Merck Sharp & DohmeTel .: +370.5.2780.247msd_lietuva@merck.com<\/td><\/tr> Bulgaria<\/strong>Mark Harp and Doom Bulgaria BulgariaTel: +359 2 819 3737info-msdbg@merck.com<\/td> Luxembourg \/ Luxemburg<\/strong>MSD BelgiumTel: +32 (0) 27766211dpoc_belux@merck.com<\/td><\/tr> Czech Republic<\/strong>Merck Sharp & Dohme sroTel .: +420.233.010.111dpoc_czechslovak@merck.com<\/td> Magyarorsz <\/strong>\u00e1 <\/strong>g<\/strong>MSD Pharma Hungary Kft.Tel .: + 36.1.888.5300hungary_msd@merck.com<\/td><\/tr> Denmark<\/strong>MSD Danmark ApSTel: + 45 4482 4000dkmail@merck.com<\/td> Malta<\/strong>Merck Sharp & Dohme Cyprus Limited.Tel: 8007 4433 (+356 99917558)malta_info@merck.com<\/td><\/tr> Germany<\/strong>MSD Sharp & Dohme GmbHTel: 0800 673 673 673 (+49 (0) 89 4561 2612)e-mail@msd.de<\/td> The Netherlands<\/strong>Merck Sharp & Dohme BVTel: 0800 9999000(+31 23 5153153)medicalinfo.nl@merck.com<\/td><\/tr> Eesti<\/strong>Merck Sharp & Dohme O\u00dcTel: +372.6144 200msdeesti@merck.com<\/td> Norway<\/strong>MSD (Norge) ASTel: +47 32 20 73 00msdnorge@msd.no<\/td><\/tr> Greece<\/strong>MSD \u0391.\u03a6.\u0392.\u0395.\u0395.:\u0397\u03bb: +30 210 98 97 300dpoc_greece@merck.com<\/td> Austria<\/strong>Merck Sharp & Dohme Ges.mbHTel: +43 (0) 1 26 044msd-medizin@merck.com<\/td><\/tr> Spain<\/strong>Merck Sharp & Dohme de Espa\u00f1a, SATel: +34 91 321 06 00msd_info@merck.com<\/td> Poland<\/strong>MSD Polska Sp. z ooTel .: +48.22.549.51.00msdpolska@merck.com<\/td><\/tr> France<\/strong>MSD VACCINSTel: + 33 (0) 1 80 46 40 40information.medicale@msd.com<\/td> Portugal<\/strong>Merck Sharp & Dohme, LdaTel: +351 21 4465700inform_pt@merck.com<\/td><\/tr> Croatia<\/strong>Merck Sharp & Dohme dooTel: +385 1 66 11 333croatia_info@merck.com<\/td> Romania<\/strong>Merck Sharp & Dohme Romania SRL Tel: + 4021 529 29 00msdromania@merck.com<\/td><\/tr> Ireland<\/strong>Merck Sharp & Dohme Ireland ( Human Health) LimitedTel: +353 (0) 1 2998700medinfo_ireland@merck.com<\/td> Slovenia<\/strong>Merck Sharp & Dohme, an innovative zdravila doo,Tel: +386.1.520.4201msd.slovenia@merck.com<\/td><\/tr> Iceland<\/strong>Vistor hf.Phone: + 354 535 7000<\/td> Slovak Republic<\/strong>Merck Sharp & Dohme, sroTel: +421.2.58282010dpoc_czechslovak@merck.com<\/td><\/tr> Italy<\/strong>MSD Italia SrlTel: +39 06 361911medicalinformation.it@merck.com<\/td> Finland \/ Finland<\/strong>MSD Finland OyPuh \/ Tel: +358 (0) 9 804 650info@msd.fi<\/td><\/tr> .\u03a0\u03c1\u03bf\u03c2<\/strong>Merck Sharp & Dohme Cyprus Limited :\u03b7\u03bb: +80000 673 (+357 22866700)cyprus_info@merck.com<\/td> Sweden<\/strong>Merck Sharp & Dohme (Sweden) ABTel: +46 77 5700488medicinskinfo@merck.com<\/td><\/tr> Latvia<\/strong>SIA Merck Sharp & Dohme Latvia Tel: +371 67364 224msd_lv@merck.com<\/td> United Kingdom (Northern Ireland)<\/strong>Merck Sharp & Dohme Ireland ( Human Health) LimitedTel: +353 (0) 1 2998700medinfoNI@msd.com<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"